CBT Stock Analysis: Cabot | NYSE

Specialty Chemicals | NYSE, USA | Market Cap: 4.461m USD | 12M Return: 10.3% | US1270551013 | Charts, Fundamentals & Technical Analysis

Reinforcing Carbons, Specialty Carbons, Fumed Silica, Fumed Alumina
Total Rating 55
Safety 82
Buy Signal 0.14
Specialty Chemicals
Industry Rotation: +1.7
Market Cap: 4.46B
Avg Turnover: 37.5M
Risk 3d forecast
Volatility30.1%
VaR 5th Pctl4.93%
VaR vs Median-0.62%
Reward TTM
Sharpe Ratio0.33
Rel. Str. IBD62.4
Rel. Str. Peer Group65.6
Character TTM
Beta0.692
Beta Downside1.051
Hurst Exponent0.465
Drawdowns 3y
Max DD48.78%
CAGR/Max DD0.19
CAGR/Mean DD0.46
EPS (Earnings per Share) EPS (Earnings per Share) of CBT over the last years for every Quarter: "2021-06": 1.35, "2021-09": 1.11, "2021-12": 1.29, "2022-03": 1.69, "2022-06": 1.73, "2022-09": 1.55, "2022-12": 0.98, "2023-03": 1.33, "2023-06": 1.42, "2023-09": 1.65, "2023-12": 1.56, "2024-03": 1.78, "2024-06": 1.92, "2024-09": 1.8, "2024-12": 1.76, "2025-03": 1.9, "2025-06": 1.9, "2025-09": 1.7, "2025-12": 1.53, "2026-03": 1.61, "2026-06": 1.67,
EPS CAGR: 6.11%
EPS Trend: 55.7%
Last SUE: 0.13
Qual. Beats: 0
Revenue Revenue of CBT over the last years for every Quarter: 2021-06: 917, 2021-09: 904, 2021-12: 968, 2022-03: 1092, 2022-06: 1149, 2022-09: 1112, 2022-12: 965, 2023-03: 1033, 2023-06: 968, 2023-09: 965, 2023-12: 958, 2024-03: 1019, 2024-06: 1016, 2024-09: 1001, 2024-12: 955, 2025-03: 936, 2025-06: 923, 2025-09: 899, 2025-12: 849, 2026-03: 904, 2026-06: 982,
Rev. CAGR: -3.77%
Rev. Trend: -83.9%
Last SUE: 1.04
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +1.5% 5
Feb +7.1% 34
Mar -2.7% 9
Apr -0.5% 19
May +7.0% 9
Jun +0.6% 18
Jul -0.3% 5
Aug -1.3% 15
Sep -2.8% 34
Oct -1.7% 14
Nov +0.2% 0
Dec -0.5% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CBT Cabot

Cabot Corporation is a U.S.-based specialty chemicals and performance materials company operating through two segments: Reinforcement Materials and Performance Chemicals. Its Reinforcement Materials business centers on carbon black, a petroleum-derived feedstock that serves as the primary reinforcing filler in rubber compounds, with the global tire industry as its dominant end-market. The Performance Chemicals segment supplies higher-value specialty carbons, fumed silica, fumed alumina, aerogels, masterbatches, conductive compounds, inkjet colorants, and carbon nanotubes to industrial customers.

Cabots products are used across tires, industrial rubber goods, lithium-ion and lead-acid batteries for electric vehicles, inks, coatings, adhesives, cosmetics, and pharmaceuticals. Distribution is handled globally through sales representatives and distributors spanning the Americas, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1882 and headquartered in Boston, Massachusetts, the company is listed on the NYSE under the ticker CBT and is classified within the Materials sector, specifically the Commodity Chemicals sub-industry.

Headlines to Watch Out For
  • Tire reinforcement demand tracks global auto and replacement tire cycles
  • EV battery adoption lifts conductive additives volume and pricing
  • Energy and feedstock costs pressure specialty chemicals margins
Piotroski VR-10 (Strict) 5.5
Net Income: 190.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.00 > 1.0
NWC/Revenue: 14.58% < 20% (prev 21.83%; Δ -7.25% < -1%)
CFO/TA 0.13 > 3% & CFO 497.0m > Net Income 190.0m
Net Debt (1.11b) to EBITDA (690.0m): 1.61 < 3
Current Ratio: 1.47 > 1.5 & < 3
Outstanding Shares: last quarter (52.0m) vs 12m ago -3.35% < -2%
Gross Margin: 22.89% > 18% (prev 25.16%; Δ -2.27% > 0.5%)
Asset Turnover: 93.04% > 50% (prev 99.43%; Δ -6.39% > 0%)
Interest Coverage Ratio: 6.80 > 6 (EBIT TTM 510.0m / Interest Expense TTM 75.0m)
Altman Z'' 4.00
A: 0.13 (Total Current Assets 1.67b - Total Current Liabilities 1.14b) / Total Assets 3.98b
B: 0.46 (Retained Earnings 1.82b / Total Assets 3.98b)
C: 0.13 (EBIT TTM 510.0m / Avg Total Assets 3.91b)
D: 0.72 (Book Value of Equity 1.60b / Total Liabilities 2.24b)
Altman-Z'' = 4.00 = AA
Beneish M -2.93
DSRI: 1.11 (Receivables 731.0m/689.0m, Revenue 3.63b/3.81b)
GMI: 1.10 (GM 25.16% / 22.89%)
AQI: 0.93 (AQ_t 0.14 / AQ_t-1 0.15)
SGI: 0.95 (Revenue 3.63b / 3.81b)
TATA: -0.08 (NI 190.0m - CFO 497.0m) / TA 3.98b)
Beneish M = -2.93 (Cap -4..+1) = A
What is the price of CBT shares?

As of August 23, 2026, the stock is trading at USD 85.19 with a total of 250,877 shares traded. Over the past week, the price has changed by -3.06%, over one month by -4.14%, over three months by +9.33% and over the past year by +10.31%.

Current recommended Stop Loss: 81.60 (which is 4.2% or 1.3 ATR below the current price).

Is CBT a buy, sell or hold?

Cabot has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold CBT.

  • StrongBuy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the CBT price?
Analysts Target Price 91.3 7.2%
Cabot (CBT) - Fundamental Data Overview as of 20 August 2026
Market Cap USD = 4.46b (4.46b USD * 1.0 USD.USD)
P/E Trailing = 24.6154
P/E Forward = 10.6157
P/S = 1.1971
P/B = 2.7794
P/EG = 1.0017
Revenue TTM = 3.63b USD
EBIT TTM = 510.0m USD
EBITDA TTM = 690.0m USD
Long Term Debt = 828.0m USD (from longTermDebt, last quarter)
Short Term Debt = 445.0m USD (from shortTermDebt, last quarter)
Debt = 1.36b USD (from shortLongTermDebtTotal, last quarter) + Leases 85.0m
Net Debt = 1.11b USD (calculated: Debt 1.36b - CCE 250.0m)
Enterprise Value = 5.57b USD (4.46b + Debt 1.36b - CCE 250.0m)
Interest Coverage Ratio = 6.80 (Ebit TTM 510.0m / Interest Expense TTM 75.0m)
EV/FCF = 19.82x (Enterprise Value 5.57b / FCF TTM 281.0m)
FCF Yield = 5.05% (FCF TTM 281.0m / Enterprise Value 5.57b)
FCF Margin = 7.73% (FCF TTM 281.0m / Revenue TTM 3.63b)
Net Margin = 5.23% (Net Income TTM 190.0m / Revenue TTM 3.63b)
Gross Margin = 22.89% ((Revenue TTM 3.63b - Cost of Revenue TTM 2.80b) / Revenue TTM)
Gross Margin QoQ = 18.74% (prev 24.00%)
Tobins Q-Ratio = 1.40 (Enterprise Value 5.57b / Total Assets 3.98b)
Interest Expense / Debt = 5.52% (Interest Expense 75.0m / Debt 1.36b)
Taxrate = 45.45% (190.0m / 418.0m)
NOPAT = 278.2m (EBIT 510.0m * (1 - 45.45%))
Current Ratio = 1.47 (Total Current Assets 1.67b / Total Current Liabilities 1.14b)
Debt / Equity = 0.85 (Debt 1.36b / totalStockholderEquity, last quarter 1.60b)
Debt / EBITDA = 1.61 (Net Debt 1.11b / EBITDA 690.0m)
Debt / FCF = 3.94 (Net Debt 1.11b / FCF TTM 281.0m)
Total Stockholder Equity = 1.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 190.0m / Total Assets 3.98b)
RoE = 12.07% (Net Income TTM 190.0m / Total Stockholder Equity 1.57b)
RoCE = 21.23% (EBIT 510.0m / Capital Employed (Equity 1.57b + L.T.Debt 828.0m))
RoIC = 8.96% (NOPAT 278.2m / Invested Capital 3.10b)
WACC = 7.16% (E(4.46b)/V(5.82b) * Re(8.42%) + D(1.36b)/V(5.82b) * Rd(5.52%) * (1-Tc(0.45)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.09 | Cagr: -3.01%
[DCF] Terminal Value 73.10% ; FCFF base≈307.8m ; Y1≈269.9m ; Y5≈218.1m
[DCF] Fair Price = 46.34 (EV 3.50b - Net Debt 1.11b = Equity 2.39b / Shares 51.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 55.71 | EPS CAGR: 6.11% | SUE: 0.13 | # QB: 0
Revenue Correlation: -83.92 | Revenue CAGR: -3.77% | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-12-31): EPS=1.51 | Chg30d=-3.45% | Revisions=-25% | Analysts=2
EPS current Year (2026-09-30): EPS=6.34 | Chg30d=+0.28% | Revisions=+12% | GrowthEPS=-12.6% | GrowthRev=-1.4%
EPS next Year (2027-09-30): EPS=6.98 | Chg30d=-0.68% | Revisions=+12% | GrowthEPS=+10.1% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: +7% (up=6, down=5)